King Abdulaziz University

Omar D Al-hejaili

Khalid Mohamed El-Say

Tarek Abdelnapy Ahmed

Osama A A Ahmed

Hossam Samir El-Sawy

Abdullah A Alamoudi

Fathy I Abd-Allah

Hossam S El-Sawy

A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Buccal formulation of avanafil with enhanced bioavailability and prolonged duration

A transdermal film formulation containing transfersomes incorporated onto the transdermal film is provided. The transfersomes include avanafil, a phospholipid, and an edge activator, wherein the phospholipid to avanafil ratio is from 3.5:1 to 4.5:1 and wherein the edge activator has a hydrophilic-lipophilic (HLB) value of 2-4. Methods of making the transdermal film formulation and methods of delivering avanafil using the transdermal film formulation are also provided.

Transfersome-containing transdermal film formulations and methods of use

Growing community of inventors

Jeddah, Saudi Arabia

Omar D Al-hejaili